Gilberto Castañeda-Hernández
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gilberto Castañeda-Hernández has a total of 228 co-authors. Here are the top co-authors by number of shared publications:
- Mario Isidoro Ortiz
Universidad Autónoma del Estado de Hidalgo
6 shared publications - Gabriel Guízar-Sahagún
Research Unit for Neurological Diseases, Instituto Mexicano del Seguro Social, Mexico City, Mexico
5 shared publications - Hector Alejandro Cabrera Fuentes
Centro de Investigación Facultad de Medicina UNAM-UABJO, Facultad de Medicina y Cirugía, Universidad Autónoma “Benito Juárez” de Oaxaca
5 shared publications - Mara Medeiros
Unidad de Investigación y Diagnóstico en Nefrología y Metabolismo Mineral Óseo, Hospital Infantil de México Federico Gómez, Ciudad de México, Mexico
5 shared publications - Rodrigo González-Ramírez
Departamento de Farmacología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Ciudad de México, México
5 shared publications - Raquel Cariño-Cortés
Universidad Autónoma del Estado de Hidalgo, Pachuca de Soto, Hgo., México
4 shared publications
Latest Publications
- 8 August 2026
- Published by Elsevier in Trends in Biotechnology
Mexico regulates tissue transfers abroad for population genomics
- 8 August 2026
- Published by Elsevier in Trends in Biotechnology
Mexico regulates tissue transfers abroad for population genomics
- Open Access
- 21 March 2026
- Published by Springer Nature in Drug Safety
- Vol. 49 (8) , 871-882
Strengthening Pharmacovigilance in Latin America: Multidisciplinary Insights from Two ISoP Latin American Chapter Symposia
Pharmacovigilance in Latin America has witnessed notable progress in recent years, marked by advancements in regulatory frameworks, regional cooperation, and increased academic involvement. However, heterogeneity among countries, uneven institutional development, and limited resources still hinder its full impact on public health. In this context, the Latin American Chapter of the International Society of Pharmacovigilance (ISoP LATAM) has played a key role in organizing two regional symposia: Cartagena, Colombia (2023), and Merida, Mexico (2025). Through multidisciplinary roundtables and open forums, ISoP LATAM has brought together regulators, academia, healthcare professionals, researchers, patient organizations, and industry representatives to promote dialogue, identify opportunities, and propose measures to improve pharmacovigilance in the region. Discussion included regulatory harmonization and convergence, the adoption of international standards for risk management and safety reporting, and the integration of artificial intelligence and real-world evidence into pharmacovigilance systems. Participants emphasized the importance of addressing medication errors through a Human Factors/Ergonomics approach, strengthening the monitoring and regulation of biosimilars, and creating differentiated frameworks for recognizing therapeutic failures. The expansion of pharmaceutical care and the systematic inclusion of pharmacovigilance education across the health sciences’ curriculum were highlighted as priorities. The reflections from these symposia emphasize the crucial role of ISoP LATAM in providing a platform for open and multidisciplinary discussions. Shifting the focus from solely regulatory topics to a broader public health perspective and expanding the agenda to include emerging fields such as pharmacogenomics, ecopharmacovigilance, and patient engagement—while ensuring fair access to technological innovations—will be vital for enhancing drug safety in Latin America.
- 21 March 2026
- Published by Springer Nature in Drug Safety
- Vol. 49 (8) , 871-882
Open AccessStrengthening Pharmacovigilance in Latin America: Multidisciplinary Insights from Two ISoP Latin American Chapter Symposia
Pharmacovigilance in Latin America has witnessed notable progress in recent years, marked by advancements in regulatory frameworks, regional cooperation, and increased academic involvement. However, heterogeneity among countries, uneven institutional development, and limited resources still hinder its full impact on public health. In this context, the Latin American Chapter of the International Society of Pharmacovigilance (ISoP LATAM) has played a key role in organizing two regional symposia: Cartagena, Colombia (2023), and Merida, Mexico (2025). Through multidisciplinary roundtables and open forums, ISoP LATAM has brought together regulators, academia, healthcare professionals, researchers, patient organizations, and industry representatives to promote dialogue, identify opportunities, and propose measures to improve pharmacovigilance in the region. Discussion included regulatory harmonization and convergence, the adoption of international standards for risk management and safety reporting, and the integration of artificial intelligence and real-world evidence into pharmacovigilance systems. Participants emphasized the importance of addressing medication errors through a Human Factors/Ergonomics approach, strengthening the monitoring and regulation of biosimilars, and creating differentiated frameworks for recognizing therapeutic failures. The expansion of pharmaceutical care and the systematic inclusion of pharmacovigilance education across the health sciences’ curriculum were highlighted as priorities. The reflections from these symposia emphasize the crucial role of ISoP LATAM in providing a platform for open and multidisciplinary discussions. Shifting the focus from solely regulatory topics to a broader public health perspective and expanding the agenda to include emerging fields such as pharmacogenomics, ecopharmacovigilance, and patient engagement—while ensuring fair access to technological innovations—will be vital for enhancing drug safety in Latin America.
- Open Access
- 2 February 2026
- Published by Elsevier in Archives of Medical Research
- Vol. 57 (4) , 103388
Introducing an In Vivo Protocol to Evaluate Skin Penetration of Topical Drugs: Proof-of-Concept with Naproxen in Humans
- 2 February 2026
- Published by Elsevier in Archives of Medical Research
- Vol. 57 (4) , 103388
Open AccessIntroducing an In Vivo Protocol to Evaluate Skin Penetration of Topical Drugs: Proof-of-Concept with Naproxen in Humans
- Open Access
- 7 May 2025
- Published by MDPI AG in Metabolites
- Vol. 15 (5) , 314
Peripheral Antinociception Induced by Carvacrol in the Formalin Test Involves the Opioid Receptor-NO-cGMP-K+ Channel Pathway
Background/Objectives: Carvacrol is a naturally occurring phenolic monoterpene that is one of the main constituents of the essential oils of oregano (Origanum vulgare) and other herbs. Carvacrol has anti-inflammatory and antinociceptive effects. Carvacrol can activate and inhibit several second messengers and ionic channels at the systemic level. However, there is no evidence of the peripheral antinociception of carvacrol and its mechanism of action. This study was designed to determine whether the opioid receptor-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP)-K+ channel pathway is involved in the local antinociception of carvacrol. Methods: Wistar rats were injected with 1% formalin subcutaneously on the dorsal surface of the right hind paw with the vehicle or carvacrol (100–300 µg/paw). To determine whether the opioid receptor-NO-cGMP-K+ channel pathway and a biguanide-dependent mechanism are responsible for the local antinociception induced by carvacrol, the effect of the injection (10 min before the 1% formalin injection) with the corresponding vehicles, metformin, naltrexone, NG-L-nitro-arginine methyl ester (L-NAME), 1 H-(1,2,4)-oxadiazolo (4,2-a) quinoxalin-1-one (ODQ), and K+ channel blockers on the antinociception induced by local carvacrol (300 µg/paw) was determined. Results: In both phases of the formalin test, carvacrol produced antinociception. Naltrexone, metformin, L-NAME, ODQ, glibenclamide and glipizide (both ATP-sensitive K+ channel blockers), tetraethylammonium and 4-aminopyridine (voltage-gated K+ channel blockers), and apamin and charybdotoxin (Ca2+-activated K+ channel blockers) reversed the carvacrol-induced peripheral antinociception. Conclusions: The local peripheral administration of carvacrol produced significant antinociception and activated the opioid receptor-NO-cGMP-K+ channel pathway.
- 7 May 2025
- Published by MDPI AG in Metabolites
- Vol. 15 (5) , 314
Open AccessPeripheral Antinociception Induced by Carvacrol in the Formalin Test Involves the Opioid Receptor-NO-cGMP-K+ Channel Pathway
Background/Objectives: Carvacrol is a naturally occurring phenolic monoterpene that is one of the main constituents of the essential oils of oregano (Origanum vulgare) and other herbs. Carvacrol has anti-inflammatory and antinociceptive effects. Carvacrol can activate and inhibit several second messengers and ionic channels at the systemic level. However, there is no evidence of the peripheral antinociception of carvacrol and its mechanism of action. This study was designed to determine whether the opioid receptor-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP)-K+ channel pathway is involved in the local antinociception of carvacrol. Methods: Wistar rats were injected with 1% formalin subcutaneously on the dorsal surface of the right hind paw with the vehicle or carvacrol (100–300 µg/paw). To determine whether the opioid receptor-NO-cGMP-K+ channel pathway and a biguanide-dependent mechanism are responsible for the local antinociception induced by carvacrol, the effect of the injection (10 min before the 1% formalin injection) with the corresponding vehicles, metformin, naltrexone, NG-L-nitro-arginine methyl ester (L-NAME), 1 H-(1,2,4)-oxadiazolo (4,2-a) quinoxalin-1-one (ODQ), and K+ channel blockers on the antinociception induced by local carvacrol (300 µg/paw) was determined. Results: In both phases of the formalin test, carvacrol produced antinociception. Naltrexone, metformin, L-NAME, ODQ, glibenclamide and glipizide (both ATP-sensitive K+ channel blockers), tetraethylammonium and 4-aminopyridine (voltage-gated K+ channel blockers), and apamin and charybdotoxin (Ca2+-activated K+ channel blockers) reversed the carvacrol-induced peripheral antinociception. Conclusions: The local peripheral administration of carvacrol produced significant antinociception and activated the opioid receptor-NO-cGMP-K+ channel pathway.
- Open Access
- 30 April 2025
- Published by The Korean Society of Food Science and Nutrition in Preventive Nutrition and Food Science
- Vol. 30 (2) , 132-140
Antioxidative Action of Alpha-Linolenic Acid during Its Gastroprotective Effect in an Indomethacin-Induced Gastric Injury Model
Cristina Salinas-Nolasco, Elizabeth Pérez-Hernández, Secilia Garza, Hui Gyu Park, J. Thomas Brenna, Gilberto Castañeda-Hernández, César A.S. Reyes-López, Nury Pérez-Hernández, and Aracely Evangelina Chávez-Piña. Prev Nutr Food Sci 2025;30:132-40. https://doi.org/10.3746/pnf.2025.30.2.132
- 30 April 2025
- Published by The Korean Society of Food Science and Nutrition in Preventive Nutrition and Food Science
- Vol. 30 (2) , 132-140
Open AccessAntioxidative Action of Alpha-Linolenic Acid during Its Gastroprotective Effect in an Indomethacin-Induced Gastric Injury Model
Cristina Salinas-Nolasco, Elizabeth Pérez-Hernández, Secilia Garza, Hui Gyu Park, J. Thomas Brenna, Gilberto Castañeda-Hernández, César A.S. Reyes-López, Nury Pérez-Hernández, and Aracely Evangelina Chávez-Piña. Prev Nutr Food Sci 2025;30:132-40. https://doi.org/10.3746/pnf.2025.30.2.132
- Open Access
- 10 April 2025
- Published by MDPI AG in Preprints.org
Peripheral Antinociception Induced by Carvacrol in the Formalin Test Involves the Opioid Receptor-NO-cGMP-K+ Channels Pathway
Background/Objectives: Carvacrol is a naturally occurring phenolic monoterpene that is one of the major constituents of the essential oils of oregano (Origanum vulgare), thyme (Thymus vulgaris) and other herbs. Carvacrol has anti-inflammatory and antinociceptive effects. At the systemic level, carvacrol is able to activate and inhibit several second messengers and ion channels. However, there is no evidence on the peripheral antinociception of carvacrol and its probable mechanism of action. The aim of this study was to investigate whether the local antinociception of carvacrol involves the opioid receptor-nitric oxide (NO)-GMP-K+ channel pathway. Methods: Formalin (1%) was injected into the dorsal surface of the right hind paw of Wistar rats. Rats received a subcutaneous injection into the dorsal surface of the paw of vehicle or carvacrol (100-300 µg/paw). To determine whether the local antinociception induced by carvacrol was mediated by the opioid receptor-NO-cGMP-K+ channel pathway and a biguanide-dependent mechanism, the effect of pretreatment (10 min before formalin injection) with the corresponding vehicles, naltrexone, L-NAME, 1 H-(1,2,4)-oxadiazolo (4,2-a) quinoxalin-1-one (ODQ), K+ channel blockers, and metformin on the antinociceptive effects induced by local carvacrol (300 µg/paw) were evaluated. Results: Carvacrol produced antinociception during both phases of the formalin test. Naltrexone, L-NAME, ODQ, glibenclamide and glipizide (both ATP-sensitive K+ channel blockers), tetraethylammonium and 4-aminopyridine (both voltage-gated K+ channel blockers), apamin and charybdotoxin (both Ca2+-activated K+ channel blockers), and metformin reversed the carvacrol-induced peripheral antinociception. Conclusions: Local peripheral administration of carvacrol was able to produce significant antinociception and activate the opioid receptor-NO-cGMP-K+ channel pathway. In addition, carvacrol activated a metformin-dependent mechanism at the peripheral level.
- 10 April 2025
- Published by MDPI AG in Preprints.org
Open AccessPeripheral Antinociception Induced by Carvacrol in the Formalin Test Involves the Opioid Receptor-NO-cGMP-K+ Channels Pathway
Background/Objectives: Carvacrol is a naturally occurring phenolic monoterpene that is one of the major constituents of the essential oils of oregano (Origanum vulgare), thyme (Thymus vulgaris) and other herbs. Carvacrol has anti-inflammatory and antinociceptive effects. At the systemic level, carvacrol is able to activate and inhibit several second messengers and ion channels. However, there is no evidence on the peripheral antinociception of carvacrol and its probable mechanism of action. The aim of this study was to investigate whether the local antinociception of carvacrol involves the opioid receptor-nitric oxide (NO)-GMP-K+ channel pathway. Methods: Formalin (1%) was injected into the dorsal surface of the right hind paw of Wistar rats. Rats received a subcutaneous injection into the dorsal surface of the paw of vehicle or carvacrol (100-300 µg/paw). To determine whether the local antinociception induced by carvacrol was mediated by the opioid receptor-NO-cGMP-K+ channel pathway and a biguanide-dependent mechanism, the effect of pretreatment (10 min before formalin injection) with the corresponding vehicles, naltrexone, L-NAME, 1 H-(1,2,4)-oxadiazolo (4,2-a) quinoxalin-1-one (ODQ), K+ channel blockers, and metformin on the antinociceptive effects induced by local carvacrol (300 µg/paw) were evaluated. Results: Carvacrol produced antinociception during both phases of the formalin test. Naltrexone, L-NAME, ODQ, glibenclamide and glipizide (both ATP-sensitive K+ channel blockers), tetraethylammonium and 4-aminopyridine (both voltage-gated K+ channel blockers), apamin and charybdotoxin (both Ca2+-activated K+ channel blockers), and metformin reversed the carvacrol-induced peripheral antinociception. Conclusions: Local peripheral administration of carvacrol was able to produce significant antinociception and activate the opioid receptor-NO-cGMP-K+ channel pathway. In addition, carvacrol activated a metformin-dependent mechanism at the peripheral level.
- 9 October 2024
- Published by Springer Nature in Advances in Therapy
- Vol. 41 (12) , 4357-4368
Recommendations for Interchangeability in a Growing Biosimilar Market in Latin America
Background Biosimilars offer significant advantages for improving access to biologic treatments in Latin America. However, their uptake has been slow due to misconceptions, regulatory uncertainties, and inadequate pharmacovigilance. Objective To address these issues, Americas Health Foundation convened a multidisciplinary panel of regional experts in biosimilar use and interchangeability from Latin America. The panel assessed the current landscape and recommended steps to enhance access. Results Key recommendations include strengthening biosimilar regulations, ensuring transparent enforcement, implementing robust pharmacovigilance, and promoting collaboration among stakeholders to educate about the safety, efficacy, and economic advantages of biosimilars and their interchangeability. Conclusions By embracing biosimilars and interchangeability, Latin American countries can expand patient access, foster competition, diversify treatment sources, and enhance the sustainability of their healthcare systems. However, achieving these goals requires addressing knowledge gaps and biases among healthcare providers, patients, regulators, and government agencies. This can be accomplished through clear communication and the use of real-world evidence.
- 9 October 2024
- Published by Springer Nature in Advances in Therapy
- Vol. 41 (12) , 4357-4368
Recommendations for Interchangeability in a Growing Biosimilar Market in Latin America
Background Biosimilars offer significant advantages for improving access to biologic treatments in Latin America. However, their uptake has been slow due to misconceptions, regulatory uncertainties, and inadequate pharmacovigilance. Objective To address these issues, Americas Health Foundation convened a multidisciplinary panel of regional experts in biosimilar use and interchangeability from Latin America. The panel assessed the current landscape and recommended steps to enhance access. Results Key recommendations include strengthening biosimilar regulations, ensuring transparent enforcement, implementing robust pharmacovigilance, and promoting collaboration among stakeholders to educate about the safety, efficacy, and economic advantages of biosimilars and their interchangeability. Conclusions By embracing biosimilars and interchangeability, Latin American countries can expand patient access, foster competition, diversify treatment sources, and enhance the sustainability of their healthcare systems. However, achieving these goals requires addressing knowledge gaps and biases among healthcare providers, patients, regulators, and government agencies. This can be accomplished through clear communication and the use of real-world evidence.
- Open Access
- 14 September 2024
- Published by Open Exploration Publishing
- Vol. 2 (6) , 423-430
Selecting the best-value biosimilar in emerging countries
The aim of biosimilars is to alleviate the financial burden of biological medicinal products. A most relevant challenge for emerging countries is how to select the best option available. In most cases, price is the major determinant, as budgets are chronically scarce. However, initial savings due to price reductions can be overridden if there is a lack of supply due to product shortages or withdrawals. These events can be prevented by a best-value strategy. According to the concept of best-value medicinal products, price is only one of the various criteria to be considered. The purpose of the present paper is to provide suggestions of criteria that can be useful for selecting the best-value biological in emerging countries. Six criteria, that are not limitative, have been selected as follows: standards of regulatory approval, quality of the product, good distribution practices, security of supply, pharmacovigilance, and price.
- 14 September 2024
- Published by Open Exploration Publishing
- Vol. 2 (6) , 423-430
Open AccessSelecting the best-value biosimilar in emerging countries
The aim of biosimilars is to alleviate the financial burden of biological medicinal products. A most relevant challenge for emerging countries is how to select the best option available. In most cases, price is the major determinant, as budgets are chronically scarce. However, initial savings due to price reductions can be overridden if there is a lack of supply due to product shortages or withdrawals. These events can be prevented by a best-value strategy. According to the concept of best-value medicinal products, price is only one of the various criteria to be considered. The purpose of the present paper is to provide suggestions of criteria that can be useful for selecting the best-value biological in emerging countries. Six criteria, that are not limitative, have been selected as follows: standards of regulatory approval, quality of the product, good distribution practices, security of supply, pharmacovigilance, and price.
- Open Access
Appropriateness of Ketoanalogues of Amino Acids, Calcium Citrate, and Inulin Supplementation for CKD Management: A RAND/UCLA Consensus
Background: Current treatment for chronic kidney disease (CKD) focuses on improving manifestations and delaying progression. Nutritional approaches play a crucial role in CKD management, and various supplements have become available. Ketoanalogues of amino acids (KAs), calcium citrate, and inulin have been proposed as suitable supplements, yet their widespread use has been limited due to insufficient evidence. This study aimed to generate general guidance statements on the appropriateness of these supplements through a RAND/UCLA consensus process. Methods: A RAND/UCLA consensus panel was convened to evaluate the appropriateness of these supplements in different clinical scenarios. In this study, we present a subgroup analysis focusing on a panel of eleven clinical nephrologists from among the experts. Results: Supplementation of low-protein diets (LPDs) and very low-protein diets (VLPDs) with KA was considered appropriate to reduce manifestations and delay CKD outcomes, supplementation with calcium citrate is considered appropriate to reduce CKD manifestations, and supplementation with inulin is considered appropriate to delay CKD outcomes and manage comorbidities. Conclusions: Based on a combination of clinical experience and scientific evidence, the panel reached a consensus that KA supplementation of LPD and VLPD, calcium citrate, and inulin are appropriate in patients with CKD across various scenarios.
Open AccessAppropriateness of Ketoanalogues of Amino Acids, Calcium Citrate, and Inulin Supplementation for CKD Management: A RAND/UCLA Consensus
Background: Current treatment for chronic kidney disease (CKD) focuses on improving manifestations and delaying progression. Nutritional approaches play a crucial role in CKD management, and various supplements have become available. Ketoanalogues of amino acids (KAs), calcium citrate, and inulin have been proposed as suitable supplements, yet their widespread use has been limited due to insufficient evidence. This study aimed to generate general guidance statements on the appropriateness of these supplements through a RAND/UCLA consensus process. Methods: A RAND/UCLA consensus panel was convened to evaluate the appropriateness of these supplements in different clinical scenarios. In this study, we present a subgroup analysis focusing on a panel of eleven clinical nephrologists from among the experts. Results: Supplementation of low-protein diets (LPDs) and very low-protein diets (VLPDs) with KA was considered appropriate to reduce manifestations and delay CKD outcomes, supplementation with calcium citrate is considered appropriate to reduce CKD manifestations, and supplementation with inulin is considered appropriate to delay CKD outcomes and manage comorbidities. Conclusions: Based on a combination of clinical experience and scientific evidence, the panel reached a consensus that KA supplementation of LPD and VLPD, calcium citrate, and inulin are appropriate in patients with CKD across various scenarios.
- Open Access
- 12 August 2024
- Published by MDPI AG in Preprints.org
Appropriateness of Ketoanalogues of Aminoacids, Calcium Citrate, and Inulin Supplementation for CKD Management: A RAND/UCLA Consensus
Background: Current treatment for Chronic Kidney Disease (CKD) focuses on improving manifestations and delaying progression. Nutritional approaches play a crucial role in CKD management, and various supplements have become available. Ketoanalogues of amino acids (KA), calcum citrate, and inulin have been proposed as suitable supplements, yet their widespread use has been limited due to insufficient evidence. This study aimed to generate general guidance statements on the appropriateness of these supplements through a RAND/UCLA consensus process; Methods: A RAND/UCLA consensus panel was convened to evaluate the appropriateness of these supplements in different clinical scenarios. In this study, we present a subgroup analysis focusing on a panel of eleven clinical nephrologists from among the experts; Results: Supplementation of low protein diets (LPD) and very low protein diets (VLPD) with KA was considered appropriate to reduce manifestations and delay CKD outcomes, supplementation with calcium citrate is considered appropriate to reduce CKD manifestations, and supplementation with inulin is considered appropriate to delay CKD outcomes and manage comorbidities; Conclusions: Based on a combination of clinical experience and scientific evidence , the panel reached a consensus that KA supplementation of LPD and VLPD, calcium citrate, and inulin are appropriate in patients with CKD across various scenarios.
- 12 August 2024
- Published by MDPI AG in Preprints.org
Open AccessAppropriateness of Ketoanalogues of Aminoacids, Calcium Citrate, and Inulin Supplementation for CKD Management: A RAND/UCLA Consensus
Background: Current treatment for Chronic Kidney Disease (CKD) focuses on improving manifestations and delaying progression. Nutritional approaches play a crucial role in CKD management, and various supplements have become available. Ketoanalogues of amino acids (KA), calcum citrate, and inulin have been proposed as suitable supplements, yet their widespread use has been limited due to insufficient evidence. This study aimed to generate general guidance statements on the appropriateness of these supplements through a RAND/UCLA consensus process; Methods: A RAND/UCLA consensus panel was convened to evaluate the appropriateness of these supplements in different clinical scenarios. In this study, we present a subgroup analysis focusing on a panel of eleven clinical nephrologists from among the experts; Results: Supplementation of low protein diets (LPD) and very low protein diets (VLPD) with KA was considered appropriate to reduce manifestations and delay CKD outcomes, supplementation with calcium citrate is considered appropriate to reduce CKD manifestations, and supplementation with inulin is considered appropriate to delay CKD outcomes and manage comorbidities; Conclusions: Based on a combination of clinical experience and scientific evidence , the panel reached a consensus that KA supplementation of LPD and VLPD, calcium citrate, and inulin are appropriate in patients with CKD across various scenarios.